NovoCure Limited
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| NVCR | BVS | BRKR | TLSI | ICCM | EKTA-B.ST | |
|---|---|---|---|---|---|---|
| Market cap | 1.71B | 781.98M | 9.72B | 239.53M | 3.67M | 23.36B |
| P/E (TTM) | — | 14.1 | — | — | — | — |
| Forward P/E | -20.3 | 12.5 | 26.5 | -15.6 | -0.2 | 12.6 |
| Price/book | 4.7 | 3.3 | 4.2 | 36.4 | 0.2 | 3.2 |
| Dividend yield | — | — | 0.31% | — | — | 3.99% |
| 1-year change | +29.64% | +52.67% | +62.27% | −11.39% | −96.20% | +33.96% |
| Today | +8.79% | +4.34% | +12.90% | +11.78% | +2.54% | +1.66% |
The closest companies by business and industry (Medical Devices). Prices may be delayed up to 15 min.
Latest news
All NVCR news ›Novocure outlines 2026 net revenue of $736M-$743M as it updates adjusted EBITDA to $24M-$34M
NovoCure Q3 2026 earnings: record revenue, raised guidance, and Optune Lua growth offset Optune Pax headwinds. Earnings Call Insights: NovoCure Limited (NVCR) Q3 2026 - "This quarter was marked by solid execution with continued momentum in…
NovoCure Limited (NVCR) Q3 2026 Earnings Call Transcript
NovoCure Limited (NVCR) Q3 2026 Earnings Call October 29, 2026 8:00 AM EDT Adam Daney - Head of Investor RelationsWilliam Doyle - Executive ChairmanFrank Leonard - CEO & DirectorChristoph Brackmann - Chief Financial OfficerUri Weinberg -…
NovoCure slips despite quarterly beats, updated guidance
NovoCure stock fell despite a Q3 earnings beat and higher 2026 guidance. - NovoCure (NVCR) is down ~7% in Thursday trading despite reporting Q3 financial results that beat on both lines and raising its 2026 guidance. - Revenue for the year…
Novocure to Evaluate Tumor Treating Fields Therapy with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, to Treat Pancreatic Cancer Through Clinical Trial Collaboration and Supply Agreement
Novocure (Nasdaq: NVCR) announced today that it has entered into a clinical trial collaboration and supply agreement with Verastem Oncology to evaluate the use of Novocure’s Tumor Treating Fields (TTFields) therapy with chemotherapy and…
NovoCure (NVCR) Expected to Post Quarterly Earnings on Thursday
Posted by Mitch Edgeman on Oct 27th, 2026 NASDAQ NVCR opened at $14.40 on Tuesday. The stock has a fifty day simple moving average of $16.15 and a 200-day simple moving average of $14.80. The company has a current ratio of 2.89, a quick…
2026 Best Companies to Work For Hall of Fame: Novocure
Business NH Magazine 2026 Best Companies to Work For Hall of Fame: Novocure Author Matthew J. Mowry At Novocure, supporting the well-being of its employees is central to its mission. The companyâs NovoFit Wellness Program includes the…
NovoCure (NASDAQ:NVCR) and Ambu A/S (OTCMKTS:AMBBY) Head to Head Contrast
Ambu A/S (OTCMKTS:AMBBY – Get Free Report) and NovoCure (NASDAQ:NVCR – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional…
Novocure to Report Third Quarter 2026 Financial Results
BioSpace Novocure to Report Third Quarter 2026 Financial Results BAAR, Switzerland--(BUSINESS WIRE)--Novocure (Nasdaq: NVCR) will report financial results for the third quarter 2026 on October 29, 2026, before the U.S. financial markets…
Novocure gets Japan approval for Optune Pax
Japan approved use with gemcitabine and nab-paclitaxel; Novocure's Oct. 1 release gave no Japanese shipment or coverage date. Japan has approved a wearable cancer treatment for adults with unresectable locally advanced pancreatic cancer.…
Novocure’s Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer
Optune Pax is a portable medical device that delivers Tumor Treating Fields (TTFields) non-invasively through wearable arrays. TTFields are alternating electric fields that disrupt processes critical for cancer cell division and survival,…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- seekingalpha.com4
- biospace.com1
- businessnhmagazine.com1
- defenseworld.net1
- themarketsdaily.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 8 articles, not a forecast.